Page 1

MDxHealth NEWS RELEASE - REGULATED INFORMATION 21 OCTOBER 2021 , 07:00 A.M. CET MDxHealth Provides Q3-2021 Business Update IRVINE , CA , and HERSTAL , BELGIUM – October 21 , 2021 – MDxHealth SA ( Euronext : MDXH.BR ) ( " MDxHealth " or the " Company " ) , a commercial - stage precision diagnostics company , today provided a business update for the third quarter ended September 30 , 2021 . Michael K. McGarrity , CEO of MDxHealth , commented : " As communicated in our midyear results in August , we remain firmly committed and focused on the execution of our growth strategy , despite the continued challenges presented by the virulent COVID - 19 Delta variant . Services revenue in the third quarter of 2021 increased by 23 % compared to Q3-2020 , and ConfirmMDx units , though still impacted in this quarter by the pandemic , were up 5 % from the same period last year . Despite the unavoidable challenges presented by the resurgent pandemic and its impact on screenings and patient flow , MDxHealth's strong business fundamentals and emphasis on focus and execution remain unchanged . I would also like to communicate the following evidence of our path forward to sustainable growth and value creation : • • • • • Our SelectMDx test has been included in the National Cancer Center Network ( NCCN ) Guidelines and a draft Local Coverage Determination ( LCD ) issued by Medicare . Our commercial sales team has been engaged in driving adoption of and compliance to our diagnostic pathway for prostate cancer . Our R & D focus on expansion of our menu into Active Surveillance would allow MDxHealth to be the only company in the diagnostic space to take a patient from elevated PSA all the way through the diagnostic and treatment pathway . We have introduced our first channel opportunity targeted into our urology customer base with a urinary tract infection ( UTI ) test to provide broad clinically actionable results for both organism identification and drug susceptibility , and are encouraged by our initial introduction . Finally , we remain committed to prudent financial stewardship and operating discipline . " Results for the third quarter ended September 30 , 2021 • Total revenue of $ 5.5 million , up 23 % from $ 4.5 million in Q3-2020 • Confirm MDx unit growth of 5 % compared to Q3-2020 • • SelectMDx unit decline of 1 % compared to Q3-2020 Cash and cash equivalents of $ 24.7 million as of September 30 , 2021 Summary of billable test volume ConfirmMDxⓇ SelectMDx® Recent Developments Quarter Ended September 30 2021 2020 % Change 3,748 3,218 3,579 5 % 3,267 ( 1 % ) The board of directors appointed Mr. Donnie ( Don ) M. Hardison as an independent non - executive director . Mr. Hardison was most recently the President and Chief Executive Officer , and served on the board of directors , of Biotheranostics , Inc. , a molecular diagnostic company focused on oncology , from February 2017 until it was acquired by Hologic , Inc. in February 2021. From April 2010 to March 2016 , Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics , a molecular genetic testing and information company . For more than 20 years prior to that , Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America ( LabCorp ) , Exact Sciences Corporation ,